Sunitinib Malate in Refractory Germ Cell Tumors

NCT00912912 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Slow Accrual

Conditions

Genitourinary Disease

Interventions

DRUG: Sunitinib Malate

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]